Haisco-USA Pharmaceuticals, Inc.
Haisco-USA Pharmaceuticals, Inc.
  • Company
  • R & D
  • Careers
  • Investors
  • Contact
  • 更多
    • Company
    • R & D
    • Careers
    • Investors
    • Contact
  • Company
  • R & D
  • Careers
  • Investors
  • Contact

HSK3486 Product Profile

Mechanism of Action:

  •  The primary mechanism of action for HSK3486 is to increase chloride ion influx through the gamma-aminobutyric acid receptor subtype A (GABAᴀ)-mediated ion channels to achieve central nervous system (CNS) depression
  • HSK3486 possesses a novel structure analogous to propofol; however, aims to provide clinically meaningful improvements as a result of its modified chemical structure
  • HSK3486’s structure is unique with a single-configuration R-designation chiral center and a terminal cyclopropyl group. It has been engineered to enhance the pharmacological and physicochemical properties of drug-receptor binding in a systematic manner

  •  Striving to demonstrate improvements of HSK3486 as the next generation anesthetic beyond propofol  
    • Significant reduction in local pain during injection
    • Potentially less respiratory depression, paired with high efficacy, providing an ideal depth of anesthesia 

HSK3486 Project Pipeline

 

  • To date, 25 Phase I–III clinical studies have been completed in China and Australia 
  • As of October 2020, a total of over 600 subjects have received HSK3486 
  • A Phase III, multicenter, randomized, double-blinded, propofol-controlled study evaluating HSK3486 for induction of general anesthesia in adults undergoing elective surgery has started in the US in Q1 2021   Go to ClinicalTrials.gov 
  • Another replicate Phase III study in the US evaluating HSK3486 for induction of general anesthesia in adults undergoing elective surgery is planned to start in Q3 2022 

HSK3486 Development Milestones

  • Company
  • R & D
  • Careers
  • Investors
  • Contact

Copyright © 2020  Haisco-USA Pharmaceuticals, Inc.  - All Rights Reserved.